

T.P. Garnik, V.M. Frolov, YA.A. Sotskaya,  
I.O. Shapovalova, V.O. Petrisheva

**EFFICIENCY OF THE COMBINATION OF PHYTO-  
PREPARATIONS ARTIHOL AND IMUNOPLUS IN  
TREATMENT OF PATIENTS WITH NON-ALCO-HOLIC  
STEATOHEPATITIS IN THE COMBINATION WITH  
CHRONIC UNCAL-CULOUS CHOLECYSTITIS ON THE  
CHRONIC FATIGUE SYNDROME**

**Key words:** non-alcoholic steatohepatitis, chronic uncalculous cholecystitis, chronic fatigue syndrome, lipoperoxydation, artihol, immunoplus, treatment

The influence of the combination of plant preparations artihol and immunoplus on clinical-biochemical indexes and expressed processes of lipoperoxydation at the patients nonalcoholic steatohepatitis (NASH) in the combination with chronic uncalculous cholecystitis (UCC) against the chronic fatigue syndrome (CFS) was studied. Positive influence of artihol and immunoplus on clinical and laboratory indexes and acceleration of achievement of remission of comorbid disease and increase of its duration was set. The indexes of lip peroxydation went down to the high bound of norm. Conclusion about expedience of inclusion of combination of artihol and immunoplus in a medical complex at the patients with NASH in the combination with UCC against the CFS was made.

616.36-002.35.14:578.16.32

- . . . . .
- 2 . . . . .
- ' . . . . .
- 2 . . . . .

( ) , ( ) [19, 22]. [18, 23, 24]. [20], [21]. ( ), [6, 13]. ( ) [4]. [18]. ( ) [8]. ( ) [23]. « » ( ) [14, 25]. » ( 0108 09463). [6, 13].

28 52 , 39 (60,9%), L-  
- 25 (39,1%).

[18].

[6, 13]. [3, 15].

13.06.2005 ) ( 271  
( ) « [11].  
( ) ( )

( ): , D [3, 15]. L-  
( ).

[7].  
[15].

[11].  
( 6) (B12), ( 2),  
[7, 11].

1 5% 400,0  
2 3 1 7-10 30-40  
UA/5324/01/01) ( [7].  
726 3.11.2006 . [3].  
( ), ( ) [11].  
[3, 12].  
[12], [15],  
[3, 16]. « » [5],  
(150 ), (12,5 ), (25 ), (0,125 ), (2,5 ) (0,5 ) [3]. [7]  
[16, 18].

1905 . B.C.  
(«carnis») « ' » L- ( ' )  
: « ' » ( ) ( /  
« » ( ), ( )  
[17].  
[3, 16].

( ) [2] - ( ) <0,01); 2,56 (3,2±0,2 / ; [1] ( ) 2,5 (8,0±0,3) / ( <0,01). Intel Pentium III 800 - (18,9±0,35) / Microsoft Office 97, Microsoft Excel Stadia 6.1 / prof Statistica [9]. 2,05 2 (9,2±0,18 / ; <0,001) (18,5±0,26) / ; <0,001) [9]. (9,3±0,8)%, (3,1±0,02)%, 3,0 (9,0±0, )%, 2,9 ( <0,001) ( . 1). <0,001), 28 (87,5%) 4 (12,5%) - 19 (59,4%), - 13 (40,6%). (28,5-30,1) / ), (11,8-12,5) / ), ( <0,05). 1,5 (1,87-1,92) / ^ ) (1,36-1,41) / ^ ) (7,6-8,5) ), (8,0-8,4) / ) (6,4±0,7) (15,2±1,3) (21,6±1,2) (84,3-84,9) / ), ( <0,05). (5,9±0,9) (10,8±1,3) (4,9±0,4) ( <0,05). (8,1±1,4) (6,1±0,3) ( <0,05). (14,2±1,7) (6,1±0,6) ( <0,05), (10,2±1,2) (16,3±1,8) ( . 2) (8,2±0,2) / ,

I

( ± )

		(n=32)	(n=32)	
, /	3,2±0,2	8,2±0,2***	8,0±0,3***	>0,1
, /	9,2±0,18	18,9±0,35***	18,5±0,26***	>0,1
, %	3,1±0,02	9,3±0,8***	9,0±0,6***	>0,1

: I- 3

<0,05 - \*; <0,01 - \*\* <0,001 - \*\*\*

(10,6±1,8) (16,6±2,2) ( ,0±0,4) (4,4±0,2) ( <0,05). (22,8±2,1) (9,7±0,5) ( <0,05). ( <0,05) (5,2±1,3) (9,6±1,5) ; (10,5±1,7) (4,4±0,2) ( <0,05). (5,2±1,2) (13,1±1,6) (4,5±0,2)

( <0,05). (9,7±1,4)

(6,3±1,3)

(11,8±1,4) (5,5±0,1)

( <0,05).

(3,2±1,2)

(7,6±1,3) (4,4±0,1) ( <0,05).

( ' )

2

( ± )

	( =32)	( =32)	
	15,2±1,3	21,6±1,2	<0,01
	5,9±0,9	10,8±1,3	<0,01
	8,1±1,4	14,2±1,7	<0,01
	10,2±1,2	16,3±1,8	<0,01
	10,6±1,8	16,6±2,2	<0,01
	5,2±1,3	9,6±1,5	<0,01
	13,1±1,6	22,8±2,1	<0,01
	6,1±1,5	10,5±1,7	<0,01
	5,2±1,2	9,7±1,4	<0,01
	6,3±1,3	11,8±1,4	<0,01
	3,2±1,2	7,6±1,3	<0,01

( , ), ( )

(3,6±0,3%).

2,6 ( <0,01).

( ' )

1,5 ( <0,05), 1,9

1,31 ( <0,05) ( . 3).

2,0 ( <0,01) ; <0,05), 1,7 ( <0,05)

2,3

(3,5±0,15) / , ( >0,05).

(5,4±0,2) / , 1,5

( <0,01).

1,7

(9,6±0,16) / , ( >0,05).

1.

(13,8±0,18) / ,

1,4

1,5 ( <0,01)

1,4

2.

(28,5-30,1) / ), (11,8-12,5) / ), (1,87-1,92) / ^ ), (1,36-1,41) / ^ ), (7,6-8,5) ), (8,0-8,4) / ) (84,3-84,9) / ),

3

( ± )

		(n=32)	(n=32)	
, /	3,2±0,2	3,5±0,15	5,4±0,2**	<0,01
, /	9,2±0,18	9,6±0,16	13,8±0,18**	<0,01
, %	3,1±0,02	3,6±0,3	4,7±0,4*	<0,05

3. ( ) - 2,0 ; 2,53 ; 1,7 ; 3,0 ; 1,4 ; 1,5 ; 4. « » ; 6. ( ' ( ' , ) ) ; 5. 7. ( ), » ; 1. // 1988. - 11. - 41 - 43. H£. 7. H£. 2008. - C. 7 -77. 2. // 1988. - 2. - 60-63. 8. 2000. - 6- 8. 3. : 03.11.2006 . 726. 9. .H. , 2000. - 320 .H. 4. " - 10. .H. , 2002. - 60 .H. 5. // -2005. - 2.- 72. 11. [ - .J. - : , 200 . - 633-634. 12. 6. // , 2008. - . 7, 3. - 142-146. / ( , 2000. - 170 .

19-20 2011 .). - : , 2011. - . 43-44.  
 13. -  
 14. - 1997. - 3. - 33 - 35.  
 15. - 2008. - 6 (44). - . 6-9.  
 16. - 2010. - 6 (56). - . 68-72.  
 17. - 2010. - 2 (52). - . 75-80.  
 18. - 1990 - 64 .  
 19. - 2000. - 448  
 »  
 - 2009. - 6 (50). - . 96-100.

20. -  
 21. - 2010. - 6 (56). - . 34-38.  
 22. - 2010. - 4. - . 39-45.  
 23. Moseley R. *Liver and biliary tract* Moseley R. *Curr. Opin. Gastroenterol.* - 2003. - V. 19. - P. 181 - 184.  
 24. Nesland J.M. *Chronic cholecystitis* J.M. Nesland *Ultrastruct. Pathol.* - 2004. - V. 28, 3. - P. 121 - 123  
 25. Ogden C. *The epidemiology of obesity* C.Ogden, S.Yanovski, M.Carrol *Gastroenterol.* - 2007. - Vol. 132. - P. 2087-2102.

24.06.2011

616.36-002.35.14:578.16.32

I.A. Shapovalova, T.P. Gamik  
**EFFICIENCY OF METABOLIC ACTIVE PREPARATION  
 GEPADIF AT PATIENTS WITH CHRONIC TOXIC  
 HEPATITIS, COMBINED WITH CHRONIC  
 UNCALCULOSIS CHOLECYSTITIS AND OBESITY AND  
 ITS INFLUENCE ON LIPOPEROXIDATION**

**Key words:** chronic toxic hepatitis, chronic uncalculosis cholecystitis, obesity, hepadif, treatment, lipoperoxidation  
 The efficiency of hepadif in the treatment of patients with chronic toxic hepatitis, combined with chronic uncalculosis cholecystitis and obesity was studied. It was set that application of hepadif was instrumental in the improvement of clinical symptoms, biochemical indexes which characterized the functional state of liver and normalization of maintenance in blood of products of lipoperoxidation such as malon dialdegid and dien's conjugates and was instrumental in achievement of the remission of the disease.